-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Makes Its Debut at the Dhaka Pharmaceutical Exhibition in Bangladesh
Category:
发布时间：2025-02-17
【概要描述】
In February, Dhaka, the capital of Bangladesh, enjoys a warm climate and picturesque scenery. On February 12, the 2025 Asia Pharma Expo in Dhaka, Bangladesh, grandly opened at the Bangabandhu International Conference Center. Shijiazhuang Sihua Pharmaceutical Group showcased its innovative achievements at the event, highlighting the new image of Chinese pharmaceutical companies as they pursue international expansion.
In February, Dhaka, the capital of Bangladesh, enjoys a warm climate and picturesque scenery. On February 12, the 2025 Asia Pharma Expo in Dhaka, Bangladesh, grandly opened at the Bangladesh-China Friendship Exhibition Center. Shijiazhuang Sihua Pharmaceutical Group showcased its innovative achievements at the event, highlighting the new image of Chinese pharmaceutical companies as they pursue international expansion.
According to reports, as one of the most influential pharmaceutical industry events in South Asia, this year’s exhibition has attracted more than 800 renowned pharmaceutical companies, raw-material suppliers, and industry organizations from over 30 countries and regions, and is expected to draw over 14,000 professional visitors and buyers.
“The exhibition brings together pharmaceutical manufacturers, purchasers, and industry professionals from South Asia and around the world, providing a premier platform for business交流 and collaboration,” said a representative from the Group’s API Foreign Trade Center. “The South Asian pharmaceutical market is currently one of the fastest-growing regions globally, with Bangladesh playing a leading role and serving as one of the Group’s key priority markets.” The company showcased its flagship products, including caffeine and azithromycin, as well as a wide array of innovative specialty APIs such as epalrestat, betahistine mesylate, argatroban, and the adrenaline series. Since the opening of the exhibition, these offerings have garnered extensive attention from trade visitors and industry professionals alike.
At the exhibition, the Group’s booth drew considerable attention from a large number of business visitors, who stopped to engage in discussions with the Group’s sales representatives, learning about the company’s strengths and product features while exploring potential collaboration opportunities. Several clients expressed strong interest in the Group’s specialty API products and indicated their desire to pursue further cooperation.
In recent years, the Group has been guided by both domestic and international market demand, continuously increasing its investment in innovation and accelerating the integration of API and formulation operations. To date, it holds 68 API marketing approvals, with significant improvements in the high-end, intelligent, and green supply capabilities of its product portfolio, while its network of international trade partners continues to expand.
The head of the Group’s API Foreign Trade Center stated that the next step will be to accelerate the company’s “going global” initiative, establish smooth new green channels for international expansion, enhance brand appeal and product influence, expedite integration into broader international markets, elevate the company’s level of international operations, and better support the Group’s high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091